|
1
|
WHO: Coronavirus Disease (COVID-19) Pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=EAIaIQobChMIs7fWjd206gIVx0XVCh189AGeEAAYASAAEgJ6ZvD_BwE. Accessed on July 4, 2020.
|
|
2
|
PAHO: Epidemiological Update: Novel Coronavirus (COVID-19) - 28 February 2020. https://www.paho.org/en/documents/epide-miological-update-novel-coronavirus-covid-19-28-february-2020. Accessed on July 4, 2020.
|
|
3
|
US Department of Homeland Security: Advisory memorandum on identification of essential critical infrastructure workers during COVID-19 response. Washington, DC: US Department of Homeland Security. https://www.cisa.gov/sites/default/files/publications/CISA_Guidance_on_the_Essential_Critical_Infrastructure_Workforce_Version_2.0_Updated.pdf. Accessed on July 4, 2020.
|
|
4
|
Graphics of the Coronavirus in Mexico: 20% of all infected in the country are health professionals. https://www.infobae.com/america/mexico/2020/06/17/graficas-del-coronavirus-en-mexico-20-de-todos-los-infectados-del-pais-son-profesionales-de-salud/. Accessed on July 4, 2020.
|
|
5
|
Government of Mexico: Conference June 23. Daily Technical Release. https://coronavirus.gob.mx/2020/06/23/conferencia-23-de-junio/. Accessed on July 4, 2020.
|
|
6
|
Burrer SL, de Perio MA, Hughes MM, Kuhar DT, Luckhaupt SE, McDaniel CJ, Porter RM, Silk B, Stuckey MJ and Walters M: CDC COVID-19 Response Team. Characteristics of Health Care Personnel with COVID-19 - US. February 12, April 9, 2020. MMWR Morb Mortal Wkly Rep. 69:477–481. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wei XS, Wang XR, Zhang JC, Yang WB, Ma WL, Yang BH, Jiang NC, Gao ZC, Shi HZ and Zhou Q: A cluster of health care workers with COVID-19 pneumonia caused by SARS-CoV-2. J Microbiol Immunol Infect. 54:54–60. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Heinzerling A, Stuckey MJ, Scheuer T, Xu K, Perkins KM, Resseger H, Magill S, Verani JR, Jain S, Acosta M, et al: Transmission of COVID-19 to gealth care personnel during exposures to a hospitalized patient - Solano County, California, February 2020. MMWR Morb Mortal Wkly Rep. 69:472–476. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Baker MA, Rhee C, Fiumara K, Bennett-Rizzo C, Tucker R, Williams SA, Wickner P, Beloff J, McGrath C, Poulton A, et al: COVID-19 infections among HCWs exposed to a patient with a delayed diagnosis of COVID-19. Infect Control Hosp Epidemiol. 41:1075–1076. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ruiz JA, Molina J and Nigenda G: Caleidoscopio de la Salud. Knaul F and Nigenda G (eds). FUNSALUD, México, pp115-124, 2003.
|
|
11
|
Rossignol JF: Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Res. 110:94–103. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Rossignol JF: Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 9:227–230. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Padmanabhan S and Padmanabhan K: Nitazoxanide -a potential ally in the treatment of COVID-19. ResearchGate: Feb 16, 2021 (Epub ahead of print). doi: 10.13140/RG.2.2.22854.83527.
|
|
14
|
Padmanabhan S: Potential dual therapeutic approach against SARS-CoV-2/COVID-19 with Nitazoxanide and Hydroxychloroquine. ResearchGate: Apr 13, 2020 (Epub ahead of print). doi: https://doi.org/10.13140/RG.2.2.28124.74882.
|
|
15
|
Pi-Sunyer FX: Obesity: Criteria and classification. Proc Nutr Soc. 59:505–509. 2000.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fusco FM, Pisaturo M, Iodice V, Bellopede R, Tambaro O, Parrella G, Di Flumeri G, Viglietti R, Pisapia R, Carleo MA, et al: COVID-19 infections among Healthcare Workers in an Infectious Diseases specialized setting in Naples, Southern Italy: Results of a cross-sectional surveillance study. J Hosp Infect. 105:596–600. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
24 doctors infected with Covid-19 confirmed in Tijuana hospital. https://www.jornada.com.mx/ultimas/estados/2020/04/14/reportan-a-24-medicos-infectados-por-covid-19-en-hospital-de-tijuana-2435.html. Accessed on July 4, 2020.
|
|
18
|
There are 35 cases of COVID-19 in hospital medical personnel in the State of Mexico. https://www.informador.mx/mexico/Hay-35-casos-de-COVID-19-en-personal-medico-de-hospital-en-Estado-de-Mexico-20200423-0135.html. Accessed on July 4, 2020.
|
|
19
|
IMSS reports that 20 doctors from a hospital in Tlalnepantla have COVID-19. https://politica.expansion.mx/mexico/2020/04/08/imss-reporta-que-20-medicos-de-un-hospital-en-tlalnepantla-tienencovid-19. Accessed on July 4, 2020.
|
|
20
|
COVID-19 outbreaks in Mexican hospitals set off alarms. https://www.washingtonpost.com/es/tablet/2020/04/22/los-brotes-de-covid-19-en-hospitales-de-mexico-prenden-las-alarmas/. Accessed on July 4, 2020.
|
|
21
|
Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, Wang D, Liu C, Meng Y, Cui L, et al: Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 288:128–138. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Risch HA: Early outpatient treatment of symptomatic, high-risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis. Am J Epidemiol. 189:1218–1226. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shah S, Das S, Jain A, Misra DP and Negi VS: A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Int J Rheum Dis. 23:613–619. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Das S, Bhowmick S, Tiwari S and Sen S: An updated systematic review of the therapeutic role of hydroxychloroquine in coronavirus disease-19 (COVID-19). Clin Drug Investig. 40:591–601. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chowdhury MS, Rathod J and Gernsheimer J: A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19. Acad Emerg Med. 27:493–504. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yu T, Tian C, Chu S, Zhou H, Zhang Z, Luo S, Hu D and Fan H: COVID-19 patients benefit from early antiviral treatment: A comparative, retrospective study. J Med Virol. 92:2675–2683. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM and Frieman MB: Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion. J Virol. 90:8924–8933. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Schwartz RA and Suskind RM: Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration. Dermatol Ther. 33(e13785)2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, Thiel V, Narayanan K, Makino S, Snijder EJ and van Hemert MJ: Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 92:2542–2548. 2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Cuadrado-Lavín A, Olmos JM, Cifrian JM, Gimenez T, Gandarillas MA, García-Saiz M, Rebollo MH, Martínez-Taboada V, López-Hoyos M, Fariñas MC, et al: Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. Trials. 21(472)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Haffizulla J, Hartman A, Hoppers M, Resnick H, Samudrala S, Ginocchio C, Bardin M and Rossignol JF: US Nitazoxanide Influenza Clinical Study Group. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: A double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 14:609–618. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, Ma H, Chen W, Lin Y, Zheng Y, et al: Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 63:706–711. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Rocco PR, Silva PL, Cruz FF, Junior MA, Tierno PF, Moura MA, De Oliveira LF, Lima CC, Dos Santos EA, Junior WF, et al: SARITA-2 investigators. Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. Eur Respir J Jan. 14(2003725)2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kelleni MT: Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management. Pharmacol Res. 157(104874)2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kelleni MT: Diclofenac potassium/Nitazoxanide/Azithromycin Used in Adults, Children and Pregnant Patients: A Novel Potential Game Changer COVID-19 Protocol. https://doi.org/10.31219/osf.io/vmq3y. 2021.
|
|
36
|
Siddiqui AJ, Jahan S, Ashraf SA, Alreshidi M, Ashraf MS, Patel M, Snoussi M, Singh R and Adnan M: Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2. J Biomol Struct Dyn August. 5:1–14. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Sayed AM, Khalaf AM, Abdelrahim ME and Elgendy MO: Repurposing of some anti-infective drugs for COVID-19 treatment: A surveillance study supported by an in silico investigation. Int J Clin Pract Dec. 9(e13877)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Olagunju A, Fowotade A, Olagunoye A, Ojo TO, Adefuye BO, Fagbamigbe AF, Adebiyi AO, Olagunju OI, Ladipo OT, Akinloye A, et al: Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. Trials. 22(3)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Martins-Filho PR, Barreto-Alves JA and Fakhouri R: Potential role for nitazoxanide in treating SARS-CoV-2 infection. Am J Physiol Lung Cell Mol Physiol. 319:L35–L36. 2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Stachulski AV, Taujanskas J, Pate SL, Rajoli RKR, Aljayyoussi G, Pennington SH, Ward SA, Hong WD, Biagini GA, Owen A, et al: Therapeutic potential of nitazoxanide: An appropriate choice for repurposing versus SARS-CoV-2? ACS Infect Dis: Dec 22, 2020 (Epub ahead of print). doi: 10.1021/acsinfecdis.0c00478.
|
|
41
|
Rakedzon S, Neuberger A, Domb AJ, Petersiel N and Schwartz E: From hydroxychloroquine to ivermectin. What are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? J Travel Med Jan. 22(taab005)2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ing EB, Xu QA, Salimi A and Torun N: Physician deaths from corona virus (COVID-19) disease. Occup Med (Lond). 70:370–374. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Chou R, Dana T, Buckley DI, Selph S, Fu R and Totten AM: Epidemiology of and risk factors for coronavirus infection in health care workers: A living rapid review. Ann Intern Med. 173:120–136. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Nioi M, Napoli PE, Lobina J, Fossarello M and d'Aloja E: COVID-19 and Italian healthcare workers from the initial sacrifice to the mRNA vaccine: Pandemic chrono-history, epidemiological data, Ethical Dilemmas, and Future Challenges. Front Public Health. 8(591900)2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Xiao H, Zhang Y, Kong D, Li S and Yang N: The effects of social support on sleep quality of medical staff treating patients with coronavirus disease 2019 (COVID-19) in January and February 2020 in China. Med Sci Monit. 26(e923549)2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Lai J, Ma S, Wang Y, Cai Z, Hu J, Wei N, Wu J, Du H, Chen T, Li R, et al: Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. JAMA Netw Open. 3(e203976)2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Mexico the country with the most medical personnel killed by coronavirus. https://www.forbes.com.mx/noticias-mexico-pais-con-mas-personal-medico-muerto-por-coronavirus/. Accessed on August 10, 2020.
|
|
48
|
Kichloo A, Albosta M, Kumar A, Aljadah M, Mohamed M, El-Amir Z, Wani F, Jamal S, Singh J and Kichloo A: Emerging therapeutics in the management of COVID-19. World J Virol. 10:1–29. 2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Sumon TA, Hussain MA, Hasan MT, Hasan M, Jang WJ, Bhuiya EH, Chowdhury AAM, Sharifuzzaman SM, Brown CL, Kwon HJ, et al: A revisit to the research updates of drugs, vaccines, and bioinformatics approaches in combating COVID-19 pandemic. Front Mol Biosci. 7(585899)2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Caly L, Druce JD, Catton MG, Jans DA and Wagstaff KM: The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 178(104787)2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Momekov G and Momekova D: Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Infectious Diseases (except HIV/AIDS). http://medrxiv.org/lookup/doi/10.1101/2020.04.11.20061804. Accessed on September 4, 2020.
|
